Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PCRX

Pacira BioSciences Inc

Apr 13 • 04:00PM ET

24.06

+0.27 1.13 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Apr 13, 8:05 AMPacira real-world data at AMCP 2026 show EXPAREL cuts costs and opioid use in outpatient hip and knee arthroplasty

Peers: INCY EXEL ACAD RDUS ENTA CORT ANAB LGND AMLX PBYI

| Held by: IJR VTI IWM VB AVUV VBR VXF SPSM IJT IWN

Scroll to Statements

Index	RUT	P/E	153.15	EPS (ttm)	0.16	Insider Own	4.23%	Shs Outstand	41.12M	Perf Week	8.04%
Market Cap	974.18M	Forward P/E	6.90	EPS next Y	3.49	Insider Trans	-3.57%	Shs Float	38.78M	Perf Month	2.25%
Enterprise Value	1.15B	PEG	0.32	EPS next Q	0.56	Inst Own	118.21%	Short Float	20.78%	Perf Quarter	2.25%
Income	7.03M	P/S	1.34	EPS this Y	-0.44%	Inst Trans	-3.87%	Short Ratio	9.55	Perf Half Y	4.34%
Sales	726.41M	P/B	1.43	EPS next Y	32.13%	ROA	0.50%	Short Interest	8.06M	Perf YTD	-7.03%
Book/sh	16.86	P/C	4.09	EPS next 5Y	21.67%	ROE	0.96%	52W High	27.64 -12.95%	Perf Year	-2.04%
Cash/sh	5.89	P/FCF	7.13	EPS past 3/5Y	-22.97% -45.77%	ROIC	0.64%	52W Low	18.80 27.98%	Perf 3Y	-42.97%
Dividend Est.	-	EV/EBITDA	9.66	Sales past 3/5Y	2.89% 11.07%	Gross Margin	71.50%	Volatility	3.25% 3.71%	Perf 5Y	-64.75%
Dividend TTM	-	EV/Sales	1.59	EPS Y/Y TTM	107.37%	Oper. Margin	3.92%	ATR (14)	0.86	Perf 10Y	-62.43%
Dividend Ex-Date	-	Quick Ratio	3.28	Sales Y/Y TTM	3.63%	Profit Margin	0.97%	RSI (14)	61.11	Recom	2.14
Dividend Gr. 3/5Y	- -	Current Ratio	4.54	EPS Q/Q	-88.35%	SMA20	5.08%	Beta	0.25	Target Price	28.71
Payout	0.00%	Debt/Eq	0.60	Sales Q/Q	5.14%	SMA50	7.21%	Rel Volume	0.47	Prev Close	23.79
Employees	829	LT Debt/Eq	0.59	Earnings	Feb 26 AMC	SMA200	2.26%	Avg Volume	843.98K	Price	24.06
IPO	Feb 03, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	-37.01% -1.73%	Trades		Volume	392,666	Change	1.13%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Equal Weight	$27
Nov-17-25	Initiated	H.C. Wainwright	Buy
Jul-25-25	Upgrade	Truist	Hold → Buy	$30
Jan-30-25	Upgrade	Truist	Sell → Hold	$8 → $25
Aug-13-24	Downgrade	Truist	Buy → Sell	$30 → $8
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$37 → $14
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $11
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight	$45 → $10
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight	$38 → $25
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75
Apr-21-21	Resumed	JP Morgan	Neutral	$70
Apr-09-21	Initiated	Berenberg	Buy	$93
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$86

Show Previous Ratings

Apr-13-26 08:00AM	Pacira Presents Real-World Data on EXPAREL Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures (GlobeNewswire)
Apr-08-26 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-26 08:00AM	Pacira BioSciences to Present Real-World Data on EXPAREL Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting (GlobeNewswire)
Mar-11-26 05:02PM	Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation (GlobeNewswire)
01:06PM	DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. (PR Newswire)
08:00AM	Loading…
Mar-06-26 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference (GlobeNewswire)
Mar-02-26 08:00AM	Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) (GlobeNewswire)
Feb-27-26 09:49AM	Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
08:30AM	Pacira BioSciences, Inc. Q4 2025 Earnings Call Summary (Moby)
01:12AM	Pacira BioSciences Q4 Earnings Call Highlights (MarketBeat)
12:06AM	Pacira BioSciences Inc (PCRX) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Feb-26-26 07:30PM	Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics (Zacks)
05:30PM	Pacira (PCRX) Lags Q4 Earnings and Revenue Estimates (Zacks)
04:01PM	Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
04:01PM	Loading…
Feb-12-26 04:01PM	Pacira to Report 2025 Financial Results on Thursday February 26, 2026 (GlobeNewswire)
08:00AM	Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices (GlobeNewswire)
Feb-09-26 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-26 10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
Jan-28-26 08:00AM	Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors (GlobeNewswire)
Jan-27-26 12:45PM	Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:10PM	Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-16-26 08:30AM	Do Options Traders Know Something About Pacira BioSciences Stock We Don't? (Zacks) -7.22%
Jan-14-26 10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
Jan-13-26 08:00AM	Pacira Announces Agreement with LG Chem to Make EXPAREL Available in Select Asian-Pacific Markets (GlobeNewswire) -5.80%
Jan-12-26 10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
Jan-08-26 04:01PM	Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues (GlobeNewswire) -9.57%
Jan-07-26 08:00AM	Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences (GlobeNewswire)
Dec-31-25 10:45AM	DOMA intends to nominate three director candidates at Pacira annual meeting (TipRanks)
Dec-30-25 10:41AM	DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. (PR Newswire)
08:00AM	Loading…
Dec-18-25 08:00AM	Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care (GlobeNewswire)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-16-25 02:10PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-03-25 10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-25 08:00AM	Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera Compared to Radiofrequency Ablation in Chronic Low Back Pain (GlobeNewswire)
Nov-26-25 04:01PM	Pacira BioSciences Files EXPAREL Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical (GlobeNewswire)
Nov-14-25 06:00PM	Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-11-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
Nov-10-25 08:09PM	DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business (PR Newswire)
Nov-07-25 12:02AM	Pacira BioSciences Inc (PCRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-25 06:30PM	Pacira (PCRX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
06:10PM	Pacira (PCRX) Tops Q3 Earnings Estimates (Zacks)
05:06PM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance (GlobeNewswire)
Nov-05-25 08:00AM	Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Nov-04-25 07:00AM	Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control (GlobeNewswire)
Oct-30-25 10:00AM	Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline (Zacks)
08:00AM	Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025 (GlobeNewswire)
Oct-29-25 10:00AM	Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 08:00AM	Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee (GlobeNewswire)
Oct-27-25 08:00AM	Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL (GlobeNewswire)
Oct-23-25 08:00AM	Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL (GlobeNewswire)
Oct-21-25 12:10PM	Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:30AM	Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL (GlobeNewswire)
Oct-20-25 04:01PM	Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy (GlobeNewswire)
Oct-03-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-25 06:04PM	Hanesbrands, Rogers, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-06-25 03:27AM	Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... (GuruFocus.com)
Aug-05-25 08:00PM	Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings (Zacks)
05:35PM	Pacira (PCRX) Tops Q2 Earnings Estimates (Zacks)
04:35PM	Pacira: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:45AM	What To Expect From Pacira BioSciences Inc (PCRX) Q2 2025 Earnings (GuruFocus.com)
Jul-31-25 12:12PM	PharmaCorp Announces Filing of Annual Information Form (GlobeNewswire)
Jul-24-25 08:00AM	Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 (GlobeNewswire)
Jul-22-25 08:00AM	Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts (GlobeNewswire)
Jul-16-25 08:40AM	Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit (PR Newswire)
Jul-10-25 11:41AM	Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement (Insider Monkey)
Jul-03-25 04:01PM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-18-25 11:06AM	Is the Options Market Predicting a Spike in Pacira BioSciences Stock? (Zacks)
08:00AM	Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient's Journey to Pain Relief and Innovation in Care at BIO 2025 (GlobeNewswire)
Jun-11-25 08:00AM	Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee (GlobeNewswire)
Jun-05-25 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 02:02PM	PharmaCorp Rx Inc. Reports First Quarter 2025 Results and Announces Non-Binding Letters of Intent to Acquire Four Pharmacies (GlobeNewswire)
May-15-25 08:00AM	Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee (GlobeNewswire)
May-14-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
May-13-25 10:35AM	Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation (PR Newswire) -6.74%
May-09-25 11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
03:41AM	Pacira BioSciences Inc (PCRX) Q1 2025 Earnings Call Highlights: Strong EXPAREL Sales and ... (GuruFocus.com)
May-08-25 05:30PM	Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Pacira (PCRX) Q1 Earnings Surpass Estimates (Zacks)
04:11PM	Pacira: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Pacira BioSciences Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 05:20PM	Pacira BioSciences Q1 2025 Earnings Preview (Seeking Alpha)
10:20AM	Pacira BioSciences Inc (PCRX) Q1 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
May-06-25 06:05PM	Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis (GlobeNewswire)
May-05-25 09:13AM	5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates (Zacks)
May-02-25 08:00AM	Pacira BioSciences to Present New Data on Clinical Immunogenicity of Intra-Articular PCRX-201 and Its Implications for Dosing Strategy in Knee Osteoarthritis (GlobeNewswire)
May-01-25 05:10PM	Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates (Zacks)
10:01AM	ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
09:34AM	IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
08:32AM	Pharmacorp Completes Acquisition of Pre-1954 Charter Company in Ontario (GlobeNewswire)
Apr-29-25 10:01AM	Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:00AM	Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 (GlobeNewswire)
Apr-28-25 08:00AM	Pacira BioSciences Announces Two-Year Efficacy Data Following a Single Local Administration of PCRX-201 in Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire) +5.52%
Apr-22-25 04:01PM	Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee (GlobeNewswire)
Apr-21-25 12:10PM	Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again (Zacks) +5.07%

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SLONIN JONATHAN	Chief Medical Officer	Mar 17 '26	Sale	22.82	3,261	74,416	223,640	Mar 19 05:43 PM
Froimson Mark	Director	Mar 17 '26	Sale	21.81	500	10,905	20,136	Mar 19 05:43 PM
Froimson Mark	Director	Mar 17 '26	Proposed Sale	21.81	500	10,905		Mar 17 02:55 PM
SLONIN JONATHAN	Officer	Mar 17 '26	Proposed Sale	22.82	3,261	74,416		Mar 17 11:12 AM
RIKER LAUREN	Senior Vice President, Finance	Feb 02 '26	Sale	20.81	4,000	83,240	52,313	Feb 03 06:24 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Feb 02 '26	Sale	20.53	13,137	269,703	131,303	Feb 03 06:24 PM
RIKER LAUREN	Officer	Feb 02 '26	Proposed Sale	21.05	4,000	84,219		Feb 02 04:12 PM
WILLIAMS KRISTEN	Officer	Feb 02 '26	Proposed Sale	20.53	13,137	269,703		Feb 02 10:55 AM
RIKER LAUREN	Senior Vice President, Finance	Jan 05 '26	Sale	24.24	1,416	34,324	59,064	Jan 06 05:30 PM
RIKER LAUREN	Officer	Jan 05 '26	Proposed Sale	24.24	1,416	34,324		Jan 05 11:22 AM
Cross Shawn	Chief Financial Officer	Dec 09 '25	Option Exercise	16.45	15,896	261,489	72,146	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 10 '25	Option Exercise	16.45	9,104	149,761	65,354	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 09 '25	Sale	25.03	15,896	397,877	56,250	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 10 '25	Sale	25.14	9,104	228,875	56,250	Dec 11 09:47 PM
Cross Shawn	Officer	Dec 10 '25	Proposed Sale	25.14	9,104	228,912		Dec 10 04:41 PM
Cross Shawn	Officer	Dec 09 '25	Proposed Sale	25.03	15,896	397,837		Dec 09 04:31 PM
SLONIN JONATHAN	Chief Medical Officer	Nov 17 '25	Sale	24.09	3,960	95,396	178,367	Nov 19 04:32 PM
SLONIN JONATHAN	Officer	Nov 17 '25	Proposed Sale	24.09	3,960	95,396		Nov 17 10:25 AM
Cross Shawn	Chief Financial Officer	Nov 10 '25	Sale	22.09	12,060	266,405	56,250	Nov 13 04:13 PM
Cross Shawn	Officer	Nov 10 '25	Proposed Sale	22.09	12,060	266,405		Nov 10 10:02 AM
Ceesay Abraham	Director	Sep 04 '25	Sale	27.19	2,354	64,005	9,039	Sep 08 05:37 PM
Ceesay Abraham	Director	Sep 04 '25	Proposed Sale	27.19	2,354	64,005		Sep 04 09:40 AM
BIGAL MARCELO	Director	Aug 07 '25	Sale	23.67	4,912	116,267	11,393	Aug 11 04:09 PM
BIGAL MARCELO	Director	Aug 07 '25	Proposed Sale	23.67	4,912	116,279		Aug 07 03:17 PM
RIKER LAUREN	Senior Vice President, Finance	Jun 04 '25	Sale	26.21	5,578	146,208	59,564	Jun 05 05:40 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 04 '25	Sale	26.24	14,376	377,226	161,574	Jun 05 05:37 PM
RIKER LAUREN	Officer	Jun 04 '25	Proposed Sale	26.21	5,579	146,209		Jun 04 11:36 AM
WILLIAMS KRISTEN	Officer	Jun 04 '25	Proposed Sale	26.24	14,376	377,226		Jun 04 10:37 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PCRX

Pacira BioSciences Inc

Upgrade your Finviz experience